We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-29.74%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$243M
AUM Growth
-$369M
(-60%)
Cap. Flow
-$216M
Cap. Flow
% of AUM
-88.84%
Top 10 Holdings %
Top 10 Hldgs %
9.9%
Holding
504
New
52
Increased
49
Reduced
307
Closed
94
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oxford Square Capital
OXSQ
|
+$1.88M |
| 2 |
Newmont
NEM
|
+$1.81M |
| 3 |
Brookfield Renewable
BEP
|
+$1.69M |
| 4 |
XRN
Chiron Real Estate Inc
XRN
|
+$1.68M |
| 5 |
Public Storage
PSA
|
+$1.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Reliance Steel & Aluminium
RS
|
+$4.3M |
| 2 |
Vale
VALE
|
+$4.14M |
| 3 |
DEA
Easterly Government Properties
DEA
|
+$4.07M |
| 4 |
NP
Neenah, Inc. Common Stock
NP
|
+$4.04M |
| 5 |
Arbor Realty Trust
ABR
|
+$3.91M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.56% |
| 2 | Healthcare | 19.87% |
| 3 | Real Estate | 12.49% |
| 4 | Energy | 9.44% |
| 5 | Materials | 6.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GARS
176
DELISTED
Garrison Capital Inc.
GARS
| $470K | 0.19% |
276,462
-112,772
| -29% | -$577K |
|
177
Ironwood Pharmaceuticals
IRWD
$586M
| $464K | 0.19% |
46,003
-3,882
| -8% | -$45.6K |
|
178
Neurocrine Biosciences
NBIX
$18.2B
| $461K | 0.19% |
5,322
-449
| -8% | -$43.9K |
|
|
CCXI
179
DELISTED
ChemoCentryx, Inc.
CCXI
| $460K | 0.19% |
11,447
-1,668
| -13% | -$70.8K |
|
180
Enanta Pharmaceuticals
ENTA
$362M
| $454K | 0.19% |
8,831
-745
| -8% | -$39.7K |
|
181
Axsome Therapeutics
AXSM
$11.7B
| $452K | 0.19% |
7,688
-1,113
| -13% | -$90.7K |
|
182
Agios Pharmaceuticals
AGIO
$2.08B
| $447K | 0.18% |
12,600
-1,063
| -8% | -$49.1K |
|
183
Ionis Pharmaceuticals
IONS
$8.93B
| $441K | 0.18% |
9,329
-787
| -8% | -$43.9K |
|
184
Sarepta Therapeutics
SRPT
$1.64B
| $436K | 0.18% |
4,457
-376
| -8% | -$43K |
|
|
AKCA
185
DELISTED
Akcea Therapeutics Inc
AKCA
| $436K | 0.18% |
30,486
-2,573
| -8% | -$42.2K |
|
186
Viper Energy
VNOM
$8.43B
| $435K | 0.18% |
65,625
-54,794
| -46% | -$995K |
|
|
ITCI
187
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $431K | 0.18% |
28,050
-4,089
| -13% | -$88.8K |
|
|
PRNB
188
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $430K | 0.18% |
7,235
-1,042
| -13% | -$60.7K |
|
189
Alector
ALEC
$169M
| $429K | 0.18% |
17,794
-2,590
| -13% | -$66K |
|
190
Akebia Therapeutics
AKBA
$338M
| $427K | 0.18% |
56,270
-8,206
| -13% | -$63.8K |
|
191
Fate Therapeutics
FATE
$275M
| $425K | 0.17% |
19,135
-2,782
| -13% | -$70.4K |
|
192
Quince Therapeutics
QNCX
$21.5M
| $420K | 0.17% |
46
-7
| -13% | -$69.1K |
|
|
TBIO
193
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $415K | 0.17% |
41,612
-6,073
| -13% | -$49.8K |
|
194
Iovance Biotherapeutics
IOVA
$2.04B
| $412K | 0.17% |
13,751
-2,013
| -13% | -$53.4K |
|
|
ONC
195
BeOne Medicines Ltd
ONC
$33.9B
| $412K | 0.17% |
3,343
-282
| -8% | -$44.1K |
|
196
Insmed
INSM
$22.4B
| $406K | 0.17% |
25,355
-2,139
| -8% | -$50.7K |
|
197
Ligand Pharmaceuticals
LGND
$5.77B
| $403K | 0.17% |
8,892
-750
| -8% | -$42.5K |
|
198
Cytokinetics
CYTK
$10.6B
| $398K | 0.16% |
33,754
-4,932
| -13% | -$62.9K |
|
|
KRTX
199
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $397K | 0.16% |
5,516
-790
| -13% | -$67.6K |
|
|
GBT
200
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $391K | 0.16% |
7,657
-646
| -8% | -$43.3K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q1 2020 Portfolio in Review
As of Q1 2020, Virtus ETF Advisers held 504 positions worth $243M, down 60% from $612M the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
Virtus ETF Advisers withdrew a net $216M in Q1 2020, closing 94 positions and reducing 307 holdings. Its most notable exit was Reliance Steel & Aluminium, an estimated $4.3M position sold in full.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Real Estate.
Against the trend, Virtus ETF Advisers opened a new position in Newmont worth $1.82M.
- Virtus ETF Advisers's largest Q1 2020 buy was Newmont: 40,138 shares worth $1.82M.
- Virtus ETF Advisers added most to Oxford Square Capital in Q1 2020, an estimated $1.88M increase.
- Virtus ETF Advisers's biggest Q1 2020 reduction was Air Products & Chemicals, cutting an estimated $3.72M.
- Virtus ETF Advisers fully exited Reliance Steel & Aluminium in Q1 2020, selling an estimated $4.3M.
- Virtus ETF Advisers's ten largest holdings make up 9.9% of its $243M portfolio in Q1 2020.
- Virtus ETF Advisers opened 52 new positions and closed 94 in Q1 2020.
- Virtus ETF Advisers's portfolio value fell 60% quarter-over-quarter to $243M.
Based on Virtus ETF Advisers's 13F filing for Q1 2020, filed 14 May 2020.